Evidence map›Paper›PMID 34954690›Full record

ArticleAging2021

An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.

Cheng Tang, GenYi Qu, Yong Xu, Guang Yang, Jiawei Wang, Maolin Xiang

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cheng TangDepartment of Urology, The Affiliated Zhuzhou Hospital XiangYa Medical College CSU, Zhuzhou 412007, China.
GenYi QuDepartment of Urology, The Affiliated Zhuzhou Hospital XiangYa Medical College CSU, Zhuzhou 412007, China.
Yong XuDepartment of Urology, The Affiliated Zhuzhou Hospital XiangYa Medical College CSU, Zhuzhou 412007, China.
Guang YangDepartment of Urology, The Affiliated Zhuzhou Hospital XiangYa Medical College CSU, Zhuzhou 412007, China.
Jiawei WangDepartment of Urology, The Affiliated Zhuzhou Hospital XiangYa Medical College CSU, Zhuzhou 412007, China.
Maolin XiangDepartment of Urology, The Affiliated Zhuzhou Hospital XiangYa Medical College CSU, Zhuzhou 412007, China.
Zhuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveUsing model algorithms, we constructed an immune-related long non-coding RNAs (lncRNAs) risk coefficient model to predict outcomes for patients with clear cell renal cell carcinoma (ccRCC) to understand the infiltration of tumor immune cells and the sensitivity to immune-targeted drugs.

methodsOpen genes data were downloaded from The Cancer Genome Atlas and The Immunology Database and Analysis Portal, and immune-related lncRNAs were obtained through Pearson correlation analysis. R language software was used to obtain differentially expressed immune-related lncRNAs and immune-related lncRNA pairs. The model was constructed using least absolute shrinkage and selector operation regression analysis, and receiver operator characteristic curves were drawn. The Akaike information criterion was used to distinguish the high-risk from the low-risk group. We also conducted correlation analysis for the high- and low-risk subgroups.

resultsWe identified 27 immune-related lncRNAs pairs, 16 of which were included in the model construction. After merging clinical data, the areas under the curve of 1 -year, 3-year, and 5-year survival times of ccRCC patients were 0.867, 0.832, and 0.838, respectively. Subgroup analyses were conducted according to the cut-off value. We found that the high-risk group was associated with poor outcomes. The risk score and tumor stage were independent predictors of the outcome of ccRCC. The risk model predicted specific immune cell infiltration, immune checkpoint gene expression levels, and high-risk groups more sensitive to sunitinib targeted therapy.

conclusionWe obtained prognostic-related novel ccRCC markers and risk model that predicts the outcome of patients with ccRCC and helps identify those who can benefit from sunitinib.

Indexed as

RNA, Long NoncodingAlgorithmsAntineoplastic AgentsBiomarkers, TumorCarcinoma, Renal CellGene Expression ProfilingHumansKidney NeoplasmsPrognosisRisk FactorsSunitinibAntineoplastic AgentsBiomarkers, TumorRNA, Long NoncodingSunitinibclear cell renal cell carcinomaimmune-related lncRNA pairsprognosisrisk coefficient modeltargeted therapyTCGA databasetumor immune infiltration

Identifiers

PMID34954690
PMCPMC8751591
OpenAlexW4200354320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.